Cost effectiveness of empagliflozin in adult patients with chronic kidney disease in the Netherlands

Bart Slob, Tanja Fens, Maaike Weersma, Maarten Postma, Cornelis Boersma and Lisa de Jong

PLOS ONE, 2024, vol. 19, issue 12, 1-16

Abstract: Aim: The recent EMPA-KIDNEY trial showed evidence for preventing disease progression in adult patients with chronic kidney disease (CKD) treated with empagliflozin. It is however yet unknown if use of empagliflozin is cost effective in the Netherlands. We aimed to evaluate the cost effectiveness of empagliflozin in adult patients with CKD in the Netherlands. Methods: A cost-effectiveness analysis was conducted using a Markov state microsimulation model, simulating kidney progression of CKD patients with eGFR

Date: 2024
References: Add references at CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0315509 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 15509&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0315509

DOI: 10.1371/journal.pone.0315509

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().